Liposome composition and method for producing same
a technology of liposome and composition, which is applied in the direction of medical preparations, pharmaceutical non-active ingredients, nanotechnology, etc., can solve the problems of difficult to ensure long-term preservation stability, and difficult to release a drug, so as to achieve easy to secure long-term preservation stability
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
a) Preparation of Oil Phase
[0141]16.6 g of hydrogenated soybean phosphatidylcholine, 2.0 g of cholesterol and 4.3 g of N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (hereinafter, also referred to as DSPE-PEG) were taken to be a molar ratio of 76 / 19 / 5, and then 405 mL of an organic solvent (ethanol / ethyl acetate=3 / 1) was added thereto, followed by warming to 70° C. and dissolving the lipids to prepare an oil phase.
b) Preparation of Water Phase
[0142]6 mM phosphate buffer (pH 7.86) was prepared to serve as a water phase.
c) Preparation of Drug-Unencapsulated Liposome
[0143]The water phase was warmed to 70° C., the oil phase was added in such a way that a volume ratio of water phase / oil phase=8 / 3 is achieved, and then two phases were mixed using a rotary agitation type emulsification machine at circumferential speed of 20 m / s and 13000 rpm for 30 minutes. Thereafter, the organic solvent and water were evaporated by blowing with ni...
example 2
[0161]A liposome composition was prepared in the same manner as in Example 1, except that, in the preparation of an oil phase, 49.9 g of hydrogenated soybean phosphatidylcholine, 6.1 g of cholesterol and 12.9 g of DSPE-PEG were used, and a water phase / oil phase mixed liquid was mixed using a rotary agitation type emulsification machine at a circumferential speed of 19 m / s and 12000 rpm for 30 minutes, and in the drug loading step, 10×PBS (manufactured by NIPPON GENE CO., LTD.) was used in place of PBS prepared in d) of Example 1, and 10×PBS (manufactured by NIPPON GENE CO., LTD.) was used in place of 2.7-fold diluted (by weight) PBS prepared in d) of Example 1, whereby a drug-encapsulated liposome composition having a gemcitabine concentration of 0.72 mg / mL, a particle size of 84 nm, a drug unencapsulation rate of 2.1%, an inner water phase osmotic pressure of 1039 mOsm / kg, and an outer water phase osmotic pressure of 285 mOsm / kg, with the osmotic pressure of the inner water phase b...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


